Oslo Patient Achieves Long-Term HIV Remission After Stem Cell Transplant

A 63-year-old man from Norway, referred to as the “Oslo patient,” has reportedly entered long-term remission from HIV after receiving a stem cell transplant from his brother. This makes him one of only a few individuals to achieve such a milestone, according to recent studies.

Although current medications can control HIV by inhibiting its replication, the virus still persists in the body and can rebound if treatment is halted. Instances like this provide invaluable insights for researchers aiming for a complete cure.

The patient underwent a bone marrow stem cell transplant to address a rare form of blood cancer. Interestingly, it was discovered just before the procedure that his brother had a genetic mutation known to confer resistance to HIV. A team from Oslo University Hospital monitored how this transplant affected the virus.

Years after the transplant, specifically four, researchers found no traces of active HIV DNA in the individual. He was able to discontinue his HIV medication two years post-transplant, and there has been no resurgence of the virus even five years later.

The findings contribute meaningful evidence to the broader understanding of potential HIV cures. The researchers noted that such studies enhance comprehension of HIV pathology, molecular mechanisms, and predictive markers that might be useful to a wider range of patients, beyond just those treated with stem cell transplants.

The mutation in the brother’s genes, CCR5Δ32/Δ32, effectively removes a receptor on white blood cells that HIV typically exploits to enter the immune system. This alteration renders the immune system largely immune to the virus’s maneuvers.

Follow-up examinations confirmed that the transplanted immune cells had predominantly taken over. While some HIV remnants were detected, they were inactive and incapable of reconstituting a functioning virus.

Notably, previous cases of similar phenomena exist, but this instance stands out as researchers thoroughly examined the gut, a common reservoir for dormant HIV, and found no active viral DNA.

Additionally, the patient’s HIV antibodies showed a decline, and his T cells ceased responding to HIV, as if the biological memory of the virus had dissipated alongside the virus itself.

While these developments are promising, it’s important to note that stem cell transplants like this are not practical for widespread use as a cure for HIV. These procedures come with significant risks and are usually considered a last resort for patients in critical need.

Researchers highlighted that about 10-20% of individuals undergoing such transplants may face fatal outcomes within a year. In this case, the Oslo patient also encountered severe complications from the procedure, known as graft-versus-host disease, which he ultimately overcame.

This immune reaction—and potentially the medications used to manage it—might have played a role in nearly eradicating the virus, according to the research team.

Future investigations are planned, aimed at analyzing data from rare ‘cure’ cases to help decipher what these clinical successes can teach us about overcoming HIV.

In conclusion, the team stresses the necessity of conducting detailed comparisons of existing HIV cure cases to identify the most effective biomarker combinations, suggesting that individual patient data meta-analyses and further studies with standardized methodologies are essential next steps.

The findings were published in Nature Microbiology.